abs74.txt	the	siu	(société	internationale	d'urologie)-icud	(international	consultation	onurologic	diseases)	working	group	on	systemic	therapy	for	metastatic	bladdercancer	has	summarized	the	most	recent	findings	on	the	aforementioned	topic	andcame	to	conclusions	and	recommendations	according	to	the	evidence	published		ineurope	and	the	united	states		treatment	for	metastatic	uc	has	changed	a	greatdeal	recently		mainly	involving	a	move	from	chemotherapy	to	immune	checkpointblockers		this	is	particularly	true	in	platinum-refractory	disease		wheresupportive	randomized	data	exist		five	checkpoint	blockers	have	been	approved	inthis	setting	by	the	fda		avelumab		atezolizumab		durvalumab		nivolumab		andpembrolizumab		nivolumab		pembrolizumab		and	atezolizumab	have	been	approved	ineurope	
